Cited by 609Hepatocellular Carcinoma Treatment and PrognosisLiver Disease Diagnosis and TreatmentHead and Neck Cancer Studies

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team

Open access

Dyson, Jessica, Jaques, Bryan, Chattopadyhay, Dipankar, Lochan, Rajiv, Graham, Janine, Das, Debasish, Aslam, Tahira, Patanwala, Imran, Gaggar, Sameer, Cole, Michael, Sumpter, Kate, Stewart, Stephen, Rose, John, Hudson, Mark, Manas, Derek, Reeves, Helen L.·2014·Journal of Hepatology

DOI 10.1016/j.jhep.2013.08.011

Open this paper in CoChat — free account

Abstract

Background & aims Hepatocellular cancer (HCC) commonly complicates chronic liver disease and increases in incidence have been reported despite falling prevalences of viral hepatitis.Methods Following the introduction of centralised specialist teams to manage patients with cancer in England, we characterised the demographics of patients with HCC referred to the Newcastle-upon-Tyne Hospitals NHS Foundation Trust between 2000 and 2010. Regional HCC mortality data was from Public Health England.Results HCC related mortality in the region rose 1.8 fold in 10 years, from 2.0 to 3.7 per 100,000. 632 cases were reviewed centrally, with 2-3 fold increases in referrals of patients with associated hepatitis C, alcoholic liver disease or no chronic liver disease and a >10 fold increase in HCC associated with non-alcoholic fatty liver disease (NAFLD). By 2010 NAFLD accounted for 41/118 (34.8%) cases. Irrespective of associated etiologies, metabolic risk factors were present in 78/118 (66.1%) cases in 2010, associated with regional increases in obesity and diabetes. Median overall survival was just 10.7 months. Although patients with NAFLD associated HCC were older (71.3 yr vs. 67.1 yr; p<0.001) and their cancers less often detected by surveillance, their survival was similar to other etiologies. This was attributed to significantly higher incidental presentation (38.2%) and lower prevalence of cirrhosis (77.2%).Conclusions HCC related mortality is increasing, with typical patients being elderly with metabolic risk factors. The prognosis for most of the cases is poor, but older patients with co-morbidities can do well, managed, within a specialist multidisciplinary team if their cancer is detected pre-symptomatically.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2013.08.011

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,913
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Estimates of the cancer incidence and mortality in Europe in 2006
Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M., & Boyle, P. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl498 · Cited by 4,032
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Estimates of cancer incidence and mortality in Europe in 2008
Ferlay, J., Parkin, D. M., & Steliarova‐Foucher, E. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.014 · Cited by 2,323
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander‐Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,166
The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis
Ascha, M. S., Hanouneh, I. A., Lopez, R., Tamimi, T. A.-R., Feldstein, A. F., & Zein, N. N. (2010) · Hepatology · doi:10.1002/hep.23527 · Cited by 1,296

Show all 25 references

Sorted by citations

Items 501–600 of 609

Hepatobiliary tumours
Ryder, S. D. (2015) · Medicine · doi:10.1016/j.mpmed.2015.07.016 · Cited by 1
Regulators of Genetic Risk for the Progression of Non-alcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Reconstruction of Transcriptional Network and Signature-Based Metabolic Profiling
Vallejo-Ardila, D. L., Bastiani, M. A. D., & Salazar, D. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_40 · Cited by 1
Non-alcoholic fatty liver disease and the risk of malignant tumors
Livzan, M. A., Syrovenko, M. I., & Сергеевна, К. Т. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-355 · Cited by 1
Natural history of nonalcoholic fatty liver disease
Crocombe, D., & Tsochatzis, E. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00014-5 · Cited by 1
Mechanistic Insights into Proglumide’s Role in Immune Cell Efficacy and Response to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma
Doneparthi, P. S., Cao, H., Chen, W., Dou, W., Fang, H., & Smith, J. P. (2025) · Cancers · doi:10.3390/cancers17182998 · Cited by 1
“However, with the increasing prevalence of obesity, metabolic dysfunction-associated steatohepatitis (MASH) has become a new risk factor for cirrhosis and HCC [3,4].”
Real-world outcomes and predictive factors in hepatocellular carcinoma patients treated with sorafenib: an 18-month ambispective cohort analysis
Nazih, M., Khoder, A. I., Waked, I. A., Senbawy, M. S. E., Abdelsattar, S., Hassan, S. B., & Abdel-Latif, M. (2025) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-025-00892-6 · Cited by 1
Adult Non-alcoholic Fatty Liver Disease (NAFLD)
Pedersen, J. S., & Bendtsen, F. (2018) · Springer eBooks · doi:10.1007/978-3-319-98890-0_2 · Cited by 1
Transarterial Embolization Therapies in Hepatocellular Carcinoma: Principles of Management
Cross, T. J. S., & Evans, J. C. (2018) · Springer eBooks · doi:10.1007/978-3-319-92216-4_10 · Cited by 1
Gross and microscopic changes of liver neoplasms and background hepatic structures following neoadjuvant therapy
Hodgson, A., Al-Mansouri, Z., Adeyi, O. A., & Fischer, S. E. (2019) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205596 · Cited by 1
Insulin Resistance: A Link Between Obesity and Cancer
Sattar, S., Nisar, M. F., & Nwosu, O. K. (2021) · Springer eBooks · doi:10.1007/978-3-030-72999-8_5 · Cited by 1
Hepatozelluläres Karzinom bei nicht-alkoholischer Steatohepatitis
Best, J., & Canbay, A. E. (2022) · Springer eBooks · doi:10.1007/978-3-662-62484-5_23 · Cited by 1
Lebertransplantation
Perrakis, A., & Croner, R. S. (2022) · Springer eBooks · doi:10.1007/978-3-662-62484-5_24 · Cited by 1
The Role of Senescence in NASH-Related HCC
Chrysavgis, L., Papadopoulos, G., & Chatzigeorgiou, A. (2022) · Interdisciplinary cancer research · doi:10.1007/16833_2022_87 · Cited by 1
Non-alcoholic fatty liver disease: current diagnostic opportunities at different stages of the disease and scientific developments in treatment. Review
Fadieienko, G. D., & Nikiforova, Y. V. (2023) · Modern Gastroenterology · doi:10.30978/mg-2023-1-39 · Cited by 1
A prediction nomogram for hepatitis B virus-associated hepatocellular carcinoma
Zhang, Y., Wan, G., Li, H., Gao, L., Liu, N., Gao, P. H., Liu, Y., Gao, X., & Duan, X. (2023) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2023.2252546 · Cited by 1
“In the last few decades, the rise of metabolic syndrome contributing to NAFLD has increased the risk of HCC [35].”
Background
GENDER-SPECIFIC EFFECTS OF OBESITY ON ALCOHOLIC LIVER DISEASE IN OLDER ADULTS OF DIFFERENT GROUPS AGED 65 AND OVER: A CASE–CONTROL STUDY
Chen, T. (2023) · Applied Ecology and Environmental Research · doi:10.15666/aeer/2105_46054614 · Cited by 1
“Elderly patients with alcoholic liver disease usually present with overweight or obesity, which is consistent with past research findings and can be explained in several ways (Dyson et al., 2014).”
Result
Reply to “Hepatocellular carcinoma and the Newcastle-upon-Tyne area”
Anstee, Q. M., Jaques, B., Hudson, M., & Reeves, H. L. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.02.017 · Cited by 1
Identifying Hepatocellular Carcinoma (HCC) cells with cancer stem cell-like properties.
Pandit, H. (2015) · doi:10.18297/etd/2211 · Cited by 1
NAFLD
Dowman, J. K., Farrell, G. C., & Newsome, P. N. (2016) · Wiley eBooks · doi:10.1002/9781118924938.ch2 · Cited by 1
[Medical-historical survey on epilepsy and older concepts about the therapy of epilepsy].
Vencovský, E. (1972) · PubMed · Cited by 1
Genomic studies in non-alcoholic fatty liver disease
Liu, Y. (2017) · Cited by 1
HCC‐Früherkennung bei Patienten mit chronischen Lebererkrankungen
Waidmann, O., Welzel, T. M., & Trojan, J. (2014) · Die Gastroenterologie · doi:10.1007/s11377-014-0940-1
Hepatocellular carcinoma and the Newcastle-upon-Tyne area
Braillon, A. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.031
The Changing Etiology of Liver Cancer
Khan, S. A. (2015) · Hepatic Oncology · doi:10.2217/hep.15.13
OPINION Nonalcoholic fatty liver disease: new treatments
Hardy, T. L., Anstee, Q. M., & Day, C. P. (2015)
Hepatic and Extrahepatic Malignancies in NAFLD
Nascimbeni, F., & Ratziu, V. (2015) · Springer eBooks · doi:10.1007/978-3-319-20538-0_14
Diabetes and Non‐Alcoholic Fatty Liver Disease
Chitturi, S., & Farrell, G. C. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch51
Exploring circulating biomarkers in patients with hepatocellular cancer
Ogle, L. F. (2017)
Clinical Manifestations of Liver Disease in Diabetes Mellitus
Virović-Jukić, L., Forgač, J., Ogresta, D., Filipec-Kanižaj, T., & Mrzljak, A. (2018) · Clinical gastroenterology · doi:10.1007/978-3-319-75856-5_21
[Bite marks as evidence in violent incidents, rapes and murders. Report of 2 cases].
Stavrianos, C., & Hourdakis, K. (1989) · PubMed
Steatohepatitis und Steatohepatitis-getriebener Leberkrebs
Heikenwälder, M. F. (2018) · Tumordiagnostik & Therapie · doi:10.1055/a-0664-2530
“Während HCC in früheren Stadien in Überwachungsprogrammen entdeckt werden, was zu einem allgemeinen Überlebensvorteil führt, wird die Diskussion über die Kosteneffektivität und den möglichen Schaden als Folge einer Überuntersuchung falsch-positiver Tests fortgesetzt [36].”
Background
Neoplasia in Patients with Excess Fat Mass
Hurley, D. L. (2018) · Springer eBooks · doi:10.1007/978-3-319-95655-8_17
The evaluation of complications and mortality in non-alcoholic steatohepatitis-related cirrhosis
Vatansever, S., & Paköz, Z. B. (2018) · Marmara medical journal · doi:10.5472/marumj.476330
“Considering that NASH is believed to be the most common cause of HCC in the future, NASH-related HCC has begun to attract particular attention [27].”
Background
Wnt/β-Catenin mediated cancer stem cell activation in hepatocellular carcinoma.
Pandit, H. (2018) · doi:10.18297/etd/3010
Perspective directions of non-invasive diagnostics of fibrosive changes in the liver upon non-alcoholic fatty liver disease
Ахмедов, В. А., & Gaus, O. V. (2018) · Herald of Pancreatic Club · doi:10.33149/vkp.2018.02.10
On call. I have been experiencing strong muscle cramps that curl my fingers into a claw shape, which I can straighten only by using the other hand. How can I prevent this?
Kormos, W. A. (2013) · PubMed
Diabetes in Liver Disease
Kawaguchi, T., Nakano, D., & Torimura, T. (2019) · Springer eBooks · doi:10.1007/978-981-13-1465-0_7
Avaliação de polimorfismos no gene do fator de crescimento endotelial vascular (VEGF) e da metilenotetrahidrofolato redutase (MTHFR) em pacientes com carcinoma hepatocelular e infecção pelo vírus da hepatite C
de Carvalho, S. C. R. (2019) · doi:10.11606/t.5.2019.tde-17042019-092036
Diabetes and Cancer
Krajewska, J., Krajewski, W. R., & Zatoński, T. (2019) · Springer eBooks · doi:10.1007/978-3-030-11815-0_59
Genetic variation of pentraxin-3 in Egyptian patients with chronic hepatitis C virus and hepatocellular carcinoma
Harb, A. R. K., Saleh, S. R., Zahran, N. M., El-Zefzafy, W. M., Mohamed, Z. Z., & Mahmoud, O. (2020) · The Scientific Journal of Al-Azhar Medical Faculty Girls · doi:10.4103/sjamf.sjamf_39_20
Interventional Radiological Management of Hepatocellular Carcinoma
Bansal, A., & Chaturvedi, A. (2020) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/ijmpo.ijmpo_256_19
“[1] Its incidence is steadily increasing, and the common etiological factors include hepatitis B and C, alcohol‐induced chronic liver disease, and nonalcoholic fatty liver disease.[2,3] Multiple staging systems have been proposed for classifying and guiding treatment decisions based on various factors which include tu…”
Background
Liver Transplantation and NAFLD/NASH
Patrono, D., Martini, S., & Romagnoli, R. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_19
Non-invasive Diagnostic Approach to NASH: Biological Markers
Petta, S., & Giannetti, A. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_13
NAFLD, Hepatocellular Carcinoma, and Extrahepatic Cancers
Younes, R., & Bugianesi, E. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_10
Diabète et complications hépatiques
Bonnet, F. (2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00013-0
Mistranslation drives alterations in protein levels and the effects of a synonymous variant at the FGF21 locus
Bayoumi, A. (2020) · The Sydney eScholarship Repository (The University of Sydney)
Hepatitis C-Induced Hepatocellular Carcinoma in the Middle East
Al‐Busafi, S. A., & Al-Naamani, K. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-78737-0_17
Histopathological Features of the Steatohepatitic Variant of Hepatocellular Carcinoma and Its Relationship with Fatty Liver Disease
Şamdancı, E. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.99842
Main molecular mechanisms for noncommunicable diseases
Geraldi, M. V., Filho, P. S. L., Baseggio, A. M., Cazarin, C. B. B., & Maróstica, M. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823569-0.00002-3
Abstracts
Bourlière, M., & Pol, S. (2019) · Liver International · doi:10.1111/liv.14255
To study the risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease in central India
Kondhalkar, A. A., Ambad, R. S., Bhatt, N., & Jha, R. K. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns2.5021
Research Status and Prospect of Metabolic Abnormalities in Hepatocellular Carcinoma
祁, 峰. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.116394
Echografische leververvetting
Heiningen, J. S.-V., den Hoed, C. M., Bindels, P., & Elshout, G. (2021) · Huisarts en Wetenschap · doi:10.1007/s12445-021-1045-y
Natürlicher Verlauf
Demir, M., & Steffen, H. (2022) · Springer eBooks · doi:10.1007/978-3-662-62484-5_2
Papel de Nrf2 y estrés oxidativo en la progresión de esteatohepatitis no alcohólica a hepatocarcinoma
Loera-Torres, M. A., Cárdenas-Zurita, K., Rios-Garcia, E., Reyes, E. C., & Morales‐González, J. A. (2022) · Cirujano General · doi:10.35366/109314
Recent Updates in the Prevention of Nonalcoholic Fatty Liver Disease
El‐Kassas, M., Awad, A., & Méndez‐Sánchez, N. (2023) · Gene Expression · doi:10.14218/ge.2022.00005s
Diabetes and Cancer
Wojciechowska, J. K., Krajewski, W. R., Zatoński, T., & Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_63
Modulation of Alcohol-Related Liver Disease by Obesity and Diabetes
Hegmar, H., & Hagström, H. (2023) · Springer eBooks · doi:10.1007/978-3-031-32483-3_51
The Association between Four Common Polymorphisms in microRNA and Risk of Hepatocellular Carcinoma: An Updated Meta-Analysis
Chen, M., Lu, Y., Wang, X., Qin, S., Chen, H., Lu, L., & Qin, X. Y. (2023) · Iranian Journal of Public Health · doi:10.18502/ijph.v52i11.14027
Predicting Consumer Behavior Toward Healthy Beverages In Surabaya
Vaddhano, N., Sancoko, A. H., & Tulipa, D. (2023) · JEM17 Jurnal Ekonomi Manajemen · doi:10.30996/jem17.v8i2.9902
“Research suggests that many health risks may be attributable to obesity, such as cardiovascular diseases (Ortega et al., 2016), type 2 diabetes and cancer (Dyson et al., 2014), and pulmonary diseases (Lainscak et al., 2011).”
Background
Screening, Surveillance, and Prevention of Hepatocellular Carcinoma
McEneaney, L. J., Vithayathil, M. K., & Khan, S. A. (2024) · Wiley eBooks · doi:10.1002/9781119756422.ch16
Effectiveness of Chemotherapy on Long-Term Survival in a Case of Advanced Juvenile Hepatocellular Carcinoma Without Viral Hepatitis Infection
Kimura, M., Nishikawa, K., Imamura, J., & Kimura, K. (2024) · Cureus · doi:10.7759/cureus.53278
“Known risk factors and characteristics of nonviral noncirrhotic HCC include obesity, type 2 diabetes, alcohol consumption, and genetic factors, especially mutations in HCC-related genes, such as TERT, TP53, and CTNNB1 [8,9].”
Background
Macrophages and Mast Cells in the Gastric Mucosa of Patients with Obesity Undergoing Sleeve Gastrectomy
Ammendola, M., Vescio, F., Rotondo, C., Arturi, F., Luposella, M., Zuccalà, V., Battaglia, C., Laganà, D., Ranieri, G., Navarra, G., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13154434
Secular trends in the incidence, prevalence, and survival of primary liver cancer in the United Kingdom from 2000-2021: a population-based cohort studyPreprint
Cuyàs, B., Alvarado‐Tápias, E., Tan, E. H., Golozar, A., Duarte‐Salles, T., Delmestri, A., Ballbe, J. M. A., Man, W. Y., Burn, E., Guarner, C., et al. (2024) · medRxiv · doi:10.1101/2024.08.05.24311466
“A UK study showed that patients with MASLD-associated HCC were older than those with other aetiologies (71.3 years vs 67.1 years) and their cancers less often detected by surveillance (45).”
BackgroundInfluential
Effect of hydroalcoholic extract of Berberis vulgaris L. fruit on the amount of angiogenesis in the chorioallantoic membrane of chicken embryos
Roygari, F., Gholasimod, S., & Behbahan, N. G. G. (2024) · Sālnāmah va āmār. · doi:10.61186/jbums.31.1.68
HYPERTRIGLYCERIDEMIA AS A RISK FACTOR FOR NON–ALCOHOLIC FATTY LIVER DISEASE
Abbasi, S., Sadiq, S., Jadoon, S., Shazia, S., Rashid, H. U., Farooq, A., & Ahmed, Z. (2025) · Journal of Khyber College of Dentistry · doi:10.33279/jkcd.v15i01.684
Clinical and Histopathological Trends in Hepatocellular Carcinoma: A 10-Year Retrospective Analysis at a Single Institution in Saudi ArabiaPreprint
Bokhary, R., & Almohammadi, N. H. (2025) · Research Square · doi:10.21203/rs.3.rs-6234231/v1
Overview of the prevalence and features of oncological diseases in type 2 diabetes and possible immunological mechanisms
Dvoryanchikov, Y. V., Deunezhewa, S., Yatskov, I. A., & Beloglazov, V. A. (2025) · Problems of Endocrinology · doi:10.14341/probl13452
Hepatocellular carcinoma of non-viral etiology: From theory to real practice
Петкау, В. В., Krasilnikova, N. E., Николаевна, Б. Е., & Тарханов, А. А. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-260
Exploring the hepatoprotective roles of kasni (Cichorium intybus) and behidana (Cydonia oblonga) in non-alcoholic fatty liver disease: A traditional approach to a modern epidemic: A comprehensive review
Zahoor, S. A., Hussain, M. M., Ifath, J., Anjum, F., & Begum, K. (2025) · International Journal of Unani and Integrative Medicine · doi:10.33545/2616454x.2025.v9.i2b.349
Dosage Limits of Three Multifunctional Savannah Plants and Their Effects on Haematological Parameters of Albino Rats
Ojewumi, A. W., Adegoke, A. A., & Dedeke, G. A. (2025) · Journal of Medicinal Natural Products · doi:10.53941/jmnp.2025.100017
Precision prevention of liver cancer based on risk factors
Chen, J. (2025) · Exploration of Digestive Diseases · doi:10.37349/edd.2025.100595
Additional file 4 of A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521104
Additional file 1 of A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521095
Additional file 2 of Rotundic acid improves nonalcoholic steatohepatitis in mice by regulating glycolysis and the TLR4/AP1 signaling pathway
Shi, X.-Y., Zheng, X.-M., Liu, H.-J., Han, X., Zhang, L., Hu, B., & Li, S. (2024) · Figshare · doi:10.6084/m9.figshare.24742940
Additional file 10 of Rotundic acid improves nonalcoholic steatohepatitis in mice by regulating glycolysis and the TLR4/AP1 signaling pathway
Shi, X.-Y., Zheng, X.-M., Liu, H.-J., Han, X., Zhang, L., Hu, B., & Li, S. (2024) · Figshare · doi:10.6084/m9.figshare.26649228
Additional file 3 of A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521101
Additional file 9 of Rotundic acid improves nonalcoholic steatohepatitis in mice by regulating glycolysis and the TLR4/AP1 signaling pathway
Shi, X.-Y., Zheng, X.-M., Liu, H.-J., Han, X., Zhang, L., Hu, B., & Li, S. (2024) · Figshare · doi:10.6084/m9.figshare.26649225
Additional file 5 of A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521107
Additional file 1 of Rotundic acid improves nonalcoholic steatohepatitis in mice by regulating glycolysis and the TLR4/AP1 signaling pathway
Shi, X.-Y., Zheng, X.-M., Liu, H.-J., Han, X., Zhang, L., Hu, B., & Li, S. (2023) · Figshare · doi:10.6084/m9.figshare.24742024
Additional file 7 of A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521113
Additional file 12 of A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521092
Additional file 3 of Rotundic acid improves nonalcoholic steatohepatitis in mice by regulating glycolysis and the TLR4/AP1 signaling pathway
Shi, X.-Y., Zheng, X.-M., Liu, H.-J., Han, X., Zhang, L., Hu, B., & Li, S. (2024) · Figshare · doi:10.6084/m9.figshare.26649207
Additional file 2 of A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521098
Additional file 6 of Rotundic acid improves nonalcoholic steatohepatitis in mice by regulating glycolysis and the TLR4/AP1 signaling pathway
Shi, X.-Y., Zheng, X.-M., Liu, H.-J., Han, X., Zhang, L., Hu, B., & Li, S. (2024) · Figshare · doi:10.6084/m9.figshare.26649216
Additional file 11 of A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521089
Additional file 11 of Rotundic acid improves nonalcoholic steatohepatitis in mice by regulating glycolysis and the TLR4/AP1 signaling pathway
Shi, X.-Y., Zheng, X.-M., Liu, H.-J., Han, X., Zhang, L., Hu, B., & Li, S. (2024) · Figshare · doi:10.6084/m9.figshare.26649231
Additional file 6 of A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease
Ferro, Y., Pujia, R., Mazza, E., Lascala, L., Lodari, O., Maurotti, S., Pujia, A., & Montalcini, T. (2022) · Figshare · doi:10.6084/m9.figshare.20521110
Additional file 4 of Rotundic acid improves nonalcoholic steatohepatitis in mice by regulating glycolysis and the TLR4/AP1 signaling pathway
Shi, X.-Y., Zheng, X.-M., Liu, H.-J., Han, X., Zhang, L., Hu, B., & Li, S. (2024) · Figshare · doi:10.6084/m9.figshare.26649210
Additional file 5 of Rotundic acid improves nonalcoholic steatohepatitis in mice by regulating glycolysis and the TLR4/AP1 signaling pathway
Shi, X.-Y., Zheng, X.-M., Liu, H.-J., Han, X., Zhang, L., Hu, B., & Li, S. (2024) · Figshare · doi:10.6084/m9.figshare.26649213
Additional file 7 of Rotundic acid improves nonalcoholic steatohepatitis in mice by regulating glycolysis and the TLR4/AP1 signaling pathway
Shi, X.-Y., Zheng, X.-M., Liu, H.-J., Han, X., Zhang, L., Hu, B., & Li, S. (2024) · Figshare · doi:10.6084/m9.figshare.26649219
Additional file 8 of Rotundic acid improves nonalcoholic steatohepatitis in mice by regulating glycolysis and the TLR4/AP1 signaling pathway
Shi, X.-Y., Zheng, X.-M., Liu, H.-J., Han, X., Zhang, L., Hu, B., & Li, S. (2024) · Figshare · doi:10.6084/m9.figshare.26649222
Impact of metabolic syndrome components on fibrosis severity and mortality in alcohol-related liver disease
Abassa, K.-K., Yu, H., Tan, S., Li, M., Zhong, Z., Zhou, H., & Guo, Y. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113027
Umbilical Cord Mesenchymal Stem Cells and Wnt Pathway Modulation: A Novel Therapy for Liver Cirrhosis and Steatosis
Wen, Y., Amjad, N., Mukamab, O., Amissah, O. B., Xie, W., Zhou, P., Song, A., Wang, L., Li, J., Huang, R., et al. (2026) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-025-00780-3
Radiologic characteristics and prognostic outcomes in non-alcoholic fatty liver disease-related versus alcohol-related hepatocellular carcinoma: a comparative cohort study
Singh, K., Mishra, S., & Shahi, A. (2026) · International Journal of Clinical Trials · doi:10.18203/2349-3259.ijct20260361
Altérations de la polyploïdie hépatocytaire au cours du développement des hépatopathies stéatosiques dites non-alcooliques
Gentric, G. (2013) · theses.fr (ABES) · doi:10.70675/eb0d4c50z81dez4186zbf94zabbcd74f451f
Impact de l’interleukine-17 sur les cellules progénitrices intra-hépatiques au cours de la régénération et dans l’initiation tumorale du foie
Gasmi, I. (2018) · theses.fr (ABES) · doi:10.70675/06aa1dd6z0c89z4f44z80ecz3970b09cbce1
Développement d'une stratégie Cheval de Troie dans le traitement du carcinome hépatocellulaire
Nayagom, B. (2019) · theses.fr (ABES) · doi:10.70675/780d49f6zde47z4ff1z9bc4z7e014070104c
Liver pathophysiology at the single cell level : characterization of cellular heterogeneity and identification of novel therapeutic targets for chronic liver diseases and hepatocellular carcinoma
Saviano, A. (2019) · theses.fr (ABES) · doi:10.70675/13a32e69z1eb7z4416za3b9z5e1e77176186
Marqueurs diagnostiques et pronostiques de la stéatohépatite métabolique
Coilly, A. (2019) · theses.fr (ABES) · doi:10.70675/488abf31z3acfz4f13z88e2zd974ef8b9b7b

Authors: Dyson, J., Jaques, B., Chattopadyhay, D., Lochan, R., Graham, J., Das, D., Aslam, T., Patanwala, I., Gaggar, S., Cole, M., Sumpter, K., Stewart, S., Rose, J., Hudson, M., Manas, D., & Reeves, H. L.
Affiliations: Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
Newcastle University (GB)
Corresponding author: Reeves, Helen L.
ORCID: Dyson, Jessica
Das, Debasish
Patanwala, Imran
Cole, Michael
Stewart, Stephen
Hudson, Mark
Manas, Derek
Reeves, Helen L.
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2014-01
Volume: 60
Issue: 1
Pages: 110-117
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2013.08.011
OpenAlex: W2076341209
Cited by: 603
References: 25
Citations by year: 2026: 23 · 2025: 32 · 2024: 45 · 2023: 43 · 2022: 72 · 2021: 65 · 2020: 63 · 2019: 60 · 2018: 57 · 2017: 48 · 2016: 38 · 2015: 33 · 2014: 18
FWCI: 19.26
Type: journal article
Language: en
Open access: green
zenodo.org
Licence: other-oa
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, other-oa)
Newcastle University ePrints (Newcastle Univesity)
Topics: Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
Keywords: hepatocellular carcinoma, obesity, type 2 diabetes, non-alcoholic fatty liver disease, HCC mortality, chronic liver disease, hepatitis C, alcoholic liver disease, metabolic risk factors, multidisciplinary cancer care, cancer surveillance, liver cirrhosis, overall survival, cancer incidence trends
MeSH terms: Age Factors, Aged, Diabetes Mellitus, Type 2, Fatty Liver, Humans, Liver Neoplasms, Middle Aged, Obesity, Risk Factors, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks